Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
| Website | http://www.renasantbio.com |
| Employees | 34 (24 on RocketReach) |
| Industry | Biotechnology Research |
Looking for a particular Renasant Bio employee's phone or email?
Emily Conley is the CEO of Renasant Bio.
24 people are employed at Renasant Bio.